近些年来的研究表明,在缺血性中风的病理过程中Ca~(2+)起着关键作用。谷氨酸能诱导Ca~(2+)从细胞外流入细胞内导致细胞能Ca~(2+)超载。因此研究者寻求防止Ca~(2+)从细胞外进入细胞的药物来防治缺血性中风的病人。本文对现已应用于临床的Ca~(2+)拮抗剂尼莫地平和盐酸氟桂嗪以及正在研究过程中的谷氨酸受体拮抗剂的研究进展进行叙述。 Recent studies have shown that Ca2 + plays a key role in the pathological process of ischemic stroke. Glutamic acid can induce the Ca ~ (2 +) influx into the cells from outside the cells, leading to Ca ~ (2+) overload in the cells. Therefore, researchers sought to prevent Ca2 + entry into the cell from outside the cell to prevent ischemic stroke in patients. In this paper, the research progress of nimodipine and flunarizine hydrochloride which are currently used clinically as Ca 2+ antagonists and glutamate receptor antagonists under study are described.